Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Yeung2, Wendy T. Parker1, Nicola D. Roberts1, Leanne Purins1, Jodi A. Braley1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Zoe Donaldson1, Mary Leong1, Linda Fletcher1, John F. Seymour3, Andrew P. Grigg4, David M. Ross5, and Timothy P. Hughes6

Key Points

Among patients with >10% BCR-ABL1 at 3 months the poorest risk group can be distinguished by the rate of BCR-ABL1 decline from baseline.
Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow up.

http://bloodjournal.hematologylibrary.org/content/early/2014/05/23/blood...